BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
December 21 2021 - 6:00AM
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”)
(NASDAQ:BRTX), a life sciences company focused on adult stem
cell-based therapies, today announced its Chief Executive Officer,
Lance Alstodt, will be featured on the James Hicks “NewMedia Show”
on Tuesday, December 21st.
The NewMedia Show covers a range of topics and
current events. The show has a large community of subscribers
interested in science, technology, business, sports and culture.
The NewMedia Show is seen and heard across multiple social media
platforms, such as YouTube, LinkedIn, Facebook, and Twitter.
“It’s an honor to be invited on the NewMedia
Show with James Hicks. I have followed his programming and I’m very
impressed with the format of the show and the reach that he has
within his community. I look forward to the opportunity to tell our
story, review our 2021 accomplishments as well as provide an update
for the coming year,” said Lance Alstodt, CEO of BioRestorative
Therapies.
The interview may be accessed on the following
YouTube channel link: https://t.co/ZRxhxvnwqW.
About BioRestorative
Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
- Disc/Spine Program (brtxDISC™): Our
lead cell therapy candidate, BRTX-100, is a product
formulated from autologous (or a person’s own) cultured mesenchymal
stem cells collected from the patient’s bone marrow. We intend that
the product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process
utilizes proprietary technology and involves collecting a patient’s
bone marrow, isolating and culturing stem cells from the bone
marrow and cryopreserving the cells. In an outpatient
procedure, BRTX-100 is to be injected by a physician into
the patient’s damaged disc. The treatment is intended for patients
whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. We have received
authorization from the Food and Drug Administration to commence a
Phase 2 clinical trial using BRTX-100 to treat chronic
lower back pain arising from degenerative disc disease.
- Metabolic Program (ThermoStem®): We are developing a cell-based
therapy candidate to target obesity and metabolic disorders using
brown adipose (fat) derived stem cells to generate brown adipose
tissue (“BAT”). BAT is intended to mimic naturally occurring brown
adipose depots that regulate metabolic homeostasis in humans.
Initial preclinical research indicates that increased amounts of
brown fat in animals may be responsible for additional caloric
burning as well as reduced glucose and lipid levels. Researchers
have found that people with higher levels of brown fat may have a
reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:
Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024